Document is current
Any future updates will be listed below
-
Authors
Billington, E. O. https://orcid.org/0000-0002-2556-588X
Leslie, W. D.
Brown, J. P.
Prior, J. C.
Morin, S. N.
Kovacs, C. S.
Kaiser, S. M.
Lentle, B. C.
Anastassiades, T.
Towheed, T.
Kline, G. A.
-
Funding
Funding for this research was provided by:
Cumming School of Medicine, University of Calgary (10029917)
- License Information
-
More Information
Article History
Received: 20 November 2020
Accepted: 4 January 2021
First Online: 12 January 2021
Compliance with ethical standards
:
: EOB has received honoraria from Amgen and Eli-Lilly outside the submitted work. JPB has received research support from Mereo BioPharma, Radius Health and Servier; has served as a consultant for Amgen and Servier; and has served on speakers’ bureaus for Amgen. SNM has received an institutional research grant from Amgen outside the submitted work. TT has received honoraria as consulting fees from Abbvie, Sandoz, Novartis, Amgen, Janssen and Pfizer. WDL, JCP, CSK, SMK, BCL, TA and GAK have nothing to disclose.
: Ethical approval for this post-hoc analysis of CaMos data was from the University of Manitoba Health Research Ethics Board (H2004:017O [HS24265], approval date August 5 2020). For the primary CaMos study, ethics approval was granted through McGill University and the appropriate research ethics board for each of the nine participating centers.
: Signed informed consent was obtained from every study participant in accordance with the Helsinki Declaration.
: Consent to use and publish CaMos data was provided by the CaMos investigators.
: N/A
